<DOC>
	<DOCNO>NCT01133886</DOCNO>
	<brief_summary>The purpose study assess response rate 6 month Myelodysplastic Syndrome ( MDS ) patient , Chronic Myelomonocytic Leukaemia ( CMML-2 ) patient , Acute Myeloid Leukaemia ( AML ) patient 30 % bone marrow blast , treat low-dose decitabine previously fail therapy 5-azacitidine .</brief_summary>
	<brief_title>Use Decitabine Myelodysplastic Syndrome ( MDS ) Following Azacitidine ( AZA ) Failure</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Written sign informed consent . 2 . â‰¥18 year age . 3 . Diagnosed MDS 5 % marrow blast IPSS risk intermediate 2 high risk ; chronic myelomonocytic leukemia ( CMML2 ) ; AML 2030 % bone marrow blast . 4 . Patients fail therapy azacitidine . 5 . Performance status 02 ( ECOG scale ) . 6 . Adequate hepatic ( bilirubin &lt; 1.5 X ULN AST &lt; 2.5 X ULN ) renal function ( creatinine &lt; 1.5 X ULN ) . 1 . Nursing pregnant female . 2 . Females childbearing potential male willing practice effective method contraception whilst receive decitabine 2 month last infusion . 3 . Patients previous malignancy concurrent malignancy . 4 . Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure unstable angina pectoris . 5 . Ongoing oral corticosteroid permit . However , use corticosteroid ( topical inhale ) permit prophylactic steroid allow transfusion reaction . 6 . Patients receive investigational agent within 30 day precede first dose study drug . 7 . Patients receive prior intensive combination chemotherapy highdose cytarabine ( &gt; /= 1g/m*2 per dose ) . ( Prior biologic therapy , target therapy single agent chemotherapy allow ) . 8 . Patients active viral bacterial infection . Note : No patient allow enter study unless infection fully treat patient remain afebrile 7 day without antibiotic . 9 . Patients concurrent autoimmune hemolytic anemia immune thrombocytopenia . 10 . Patients previously treat decitabine . 11 . Patients know positive serology HIV . 12 . Patients condition may unable comply treatment monitoring requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>